Clinical Trials Logo

Clinical Trial Summary

The clinical trial is aimed to evaluate the anti-neovascular effect of KDR2-2 suspension eyedrop in the treatment of neovascular glaucoma. Fourty subjects would receive either 0.96 or 3.84 mg/per day/eye, in a QID fashion, ×7 days (those without complications can continue to 28 days). The anti-neovascular effect of KDR2-2 on iris neovascularization would be evaluated at day 1, day 7, day 14, day 28 after KDR2-2 usage.


Clinical Trial Description

Neovascular glaucoma (NVG) has a high blinding rate and poor prognosis. Anti-glaucoma surgery is the main stake of saving visual function and relieving pain, but the proliferation of iris neovascularization (NVI) makes it difficult to treat NVG. Normally, the patients need an intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents prior to glaucoma surgery to control the NVI proliferation. KDR2-2, a novel small-molecule tyrosine kinase inhibitor targeting VEGF receptor 2 (VEGFR2), has demonstrated anti-neovascular effect without obvious side-effects or complications in animal studies and a Phase I clinical trial (NCT04620109). In this study, 40 patients with NVG will be included to evaluate the effectiveness of KDR2-2 suspension eyedrop on NVI in NVG eyes. The included subjects would receive either 0.96 or 3.84 mg/day/eye, in a QID fashion, ×7 days (those without complications can continue to 28 days). This study aims to and propose a novel, non-invasive and more compliant method for the treatment of NVG. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04844619
Study type Interventional
Source Sun Yat-sen University
Contact Xiulan Zhang, MD, PhD
Phone +862066610720
Email zhangxl2@mail.sysu.edu.cn
Status Recruiting
Phase Phase 1
Start date April 19, 2021
Completion date February 28, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT00491712 - Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection N/A
Recruiting NCT04519619 - Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
Completed NCT01370135 - Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma N/A
Completed NCT04970251 - Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma N/A
Completed NCT02805257 - Ahmed Glaucoma Valve Surgery With Mitomycin-C Phase 2
Recruiting NCT02067013 - Analysis of Aqueous and Vitreous Humor Phase 2
Completed NCT00524758 - Oculusgen (Ologen) Glaucoma MMC Control in Estonia Phase 3
Withdrawn NCT00727038 - Lucentis for New Onset Neovascular Glaucoma Phase 1/Phase 2
Not yet recruiting NCT02947867 - Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG Phase 2/Phase 3
Completed NCT01711879 - Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma N/A
Terminated NCT02260219 - Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma N/A
Withdrawn NCT00441181 - Effects of Travoprost on Neovascular Glaucoma N/A
Completed NCT01051583 - Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma Phase 2
Completed NCT05156021 - A Study on the Treatment Strategy of NVG Secondary to PDR N/A
Terminated NCT01301378 - Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube N/A
Not yet recruiting NCT05316142 - Any Unique Identifier Assigned to the Protocol by the Sponsor N/A
Completed NCT03154892 - The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma N/A